My noble friend raises a very important point. Despite a very challenging environment, where ongoing industrial action has been planned, the number of patients waiting more than 78 weeks for care has decreased from 124,000 in September 2021 to just under 11,500 at the end of April 2023. There has been significant progress in reducing the cancer backlog, which was down by 4,500 patients at the end of April 2023 compared with the same period last year.
The level of disruption has, none the less, been significant. The main impact has been on cancer surgery, in addition to some out-patient appointments. The recent nursing and junior doctor strikes came after previous industrial action, meaning that the accumulative impact will continue for some time. The department and NHS England are monitoring the impact and, where possible, taking action to mitigate the impact on patients.
My Lords, the most recently published cancer registration statistics are for 2020—published in autumn 2022—which note severe disruption to data collection as a result of Covid. Data is still slow to come in. Is the data of the children of those who have had breast or ovarian cancer with either the BRCA 1 or 2 gene or the relevant ones for ovarian cancer being collected? They are at extremely high risk of developing cancer. Once that has been identified, they can get access to regular testing. If the Minister cannot answer that now, could he write to me with the answer to make sure that that is fed into the system?
I am grateful to the noble Baroness for raising that very important point; she is absolutely right. I cannot answer that specifically, but I can certainly take it back to the department and write to her.
My Lords, the noble Baroness, Lady Brinton, is taking part remotely.
My Lords, while it is good to hear about the audit, five months ago respected oncologist Professor Carlo Palmieri from Liverpool University estimated that the number of cases of metastatic breast cancer in England increased from more than 48,000 in 2019 to more than 57,000 in 2020-21, resulting in an increased need for clinical activity and work. What planning, design and recommissioning of appropriate cancer services have been undertaken by the NHS? Have the Government provided the extra resources needed to deliver clinical services to these patients this year?
The department has committed an additional £8 billion from 2022-23 to 2024-25, on top of the £2 billion elective recovery fund and the £700 million targeted investment fund already made available to the NHS. The Autumn Statement 2022 provided additional funding of £3.3 billion, and £3.3 billion for 2024-25, to support the NHS in managing the pressures that it faces.